The Top 5 Biosimilars Articles for the Week of January 7

The Center for Biosimilars® recaps the top news for the week of January 7, 2019.
January 11, 2019


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of January 7.

Number 5: Samsung Bioepis has announced that it will partner with biopharmaceutical company 3SBio to develop and commercialize multiple biosimilars in mainland China.

Number 4: The United Kingdom-based Patients Association recently released results of a survey and focus group that sought to understand patient needs in switching to biosimilars from reference products.

Number 3: At the J.P. Morgan Healthcare Conference, Coherus presented an overview of the company’s “branded approach” to selling its newly launched biosimilar pegfilgrastim, Udenyca.

Number 2: The Community Oncology Alliance recently formed a standing Biosimilars Committee aimed at educating providers.

Number 1: During the J.P. Morgan Healthcare Conference, Pfizer and Teva gave a look at their strategies for 2019 and beyond.

Finally, last week, our e-newsletter asked if new US policies to promote biosimilar insulins will help.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.